The Latest Cardiac and Vascular News
Successful procedures initiate U.S. limited market release MIAMI LAKES, Fla., June 16, 2022 /PRNewswire/ — Cordis, a global leader in cardiovascular technologies, today announced the first-in-human use of the Radianz Radial Peripheral System™ by Jihad Mustapha, MD, FACC, FSCAI at Advanced Cardiac & Vascular Centers […]
MENLO PARK, Calif., April 5, 2022 /PRNewswire/ — Endovascular Engineering (“E2”), a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), today announced the closing of a $15 million Series A1 financing. The financing was […]
Completes the RADIANZ Radial Peripheral System™; signals Cordis’ renewed investment in innovation MIAMI LAKES, Fla., March 10, 2022 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T. RADIANZ™ Vascular Stent […]
Cordis continues leadership team buildout with seasoned healthcare finance officer MIAMI LAKES, Fla., Dec. 16, 2021 /PRNewswire/ — Cordis, a global interventional cardiovascular technology company, today announced that Christopher Scully has joined the organization as Chief Financial Officer. He will be responsible for leading the […]
Globally recognized interventional cardiologist is the latest addition to a growing leadership team MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization’s […]
Matthew Muscari takes the helm of global marketing and American sales as Cordis pursues path of transformation and growth MIAMI LAKES, Fla., Nov. 2, 2021 /PRNewswire/ — Cordis, a global interventional vascular technology company, today announced that Matthew Muscari will assume the role […]
DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain […]
DUBLIN, Ohio, March 12, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of […]
DUBLIN, Ohio, May 14, 2019 /PRNewswire/ — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its RADIAL 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses […]
DUBLIN, Ohio, November 28, 2018 — Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an […]
